SAN DIEGO (PRWEB)
August 22, 2022
XinThera, Inc., today announced that Stephen Kaldor, Ph.D., its founder and chairman of its Board of Directors, passed away on August 8, 2022.
“We’ve lost a great leader, friend and mentor,” said Qing Dong, XinThera’s co-founder, president and CSO. “XinThera was a very important part of Steve’s distinguished career in the biotech industry. We will remember him for his kindness, generosity of spirit, and his ability to inspire. His impact on XinThera and our team will never be forgotten as we continue our mission of discovering novel therapies and carry on Steve’s legacy by realizing his vision for the company. Our deepest sympathies go out to Steve’s family and all who knew him.”
Steve was an accomplished pharmaceutical and biotechnology industry executive having started his career in 1990 as a chemist with Eli Lilly where he co-invented three marketed drugs along with multiple other compounds currently in clinical development. Prior to co-founding XinThera in early 2021 with Qing Dong, Ph.D. and Gene Hung, M.D., Steve was founding CEO of precision oncology biotech Kinnate Biopharma (NASDAQ: KNTE) from 2018 through 2020 and also served on its Board through 2021. Steve contributed to other companies including Quanticel, where he served as CEO from 2010 until it was acquired by Celgene in 2015, Ambrx, where he served as President and CEO from 2007 to 2010, and Syrrx where he was President and CSO, until its 2005 acquisition by Takeda. Steve served on several Boards throughout his career including Amira Pharmaceuticals (acquired by BMS in 2011), Crinetics (NASDAQ: CRNX), Crown Biosciences, and Furiex Pharmaceuticals (acquired in 2014 by Forest/Actavis). He also acted as an advisor to FronThera Pharmaceuticals, Foresite Capital, Versant Ventures and Thomas, McNerney and Partners. Steve was a chemist by training, having received a B.A. in chemistry from Columbia University and a Ph.D. in organic chemistry from Harvard University.
About XinThera, Inc.
XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline based in San Diego, CA.
Contact:
Mary Gieson
Sr. Director Corporate Operations
XinThera, Inc.
mgieson@xinthera.com
Share article on social media or email: